TrialLeukemia research2022

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.

Chezi Ganzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.